DDrare: Database of Drug Development for Rare Diseases

Experimental (non immunosuppressive symptomatic treatment (nist) and rituximab) (DrugBank: Rituximab)

告示番号	疾患名（ページ内リンク）	臨床試験数
222	一次性ネフローゼ症候群	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01508468 (ClinicalTrials.gov)	January 2012	9/12/2011	Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy	Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN)	Idiopathic Membranous Nephropathy	Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)	Assistance Publique - Hôpitaux de Paris	NULL	Active, not recruiting	18 Years	N/A	Both	80	Phase 3	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01508468
(ClinicalTrials.gov)

January 2012

9/12/2011

Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy

Prospective Randomized Multicentric Open Label Study to Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy (IMN)

Idiopathic Membranous Nephropathy

Drug: symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);Drug: experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)

Assistance Publique - Hôpitaux de Paris

NULL

Active, not recruiting

18 Years

N/A

Both

Phase 3

France